SHINE Technologies to acquire the SPECT business from Lantheus.

SHINE Technologies, a nuclear fusion company with a platform of medical isotope products, agreed to acquire the SPECT business from Lantheus, a radiopharmaceutical-focused company. Financial terms were not disclosed. "Today's announcement marks a major milestone on our journey to improve lives through fusion technology. Our companies have a long history of partnership, and we have admired Lantheus' commitment to ensuring patient access to essential medical radioisotopes. By integrating Lantheus' SPECT business and talented team with our company, we will expand our product portfolio, accelerate our path to market for our planned suite of isotopes and increase our market share – ultimately ensuring greater access to these life-saving products for patients," Greg Piefer, SHINE Founder and CEO.